Virax Biolabs (VRAX) said its UK subsidiary entered an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling product line. The deal is positive for future distribution and sales visibility, but no financial terms or near-term revenue impact were disclosed.
Virax Biolabs (VRAX) said its UK subsidiary entered an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling product line. The deal is positive for future distribution and sales visibility, but no financial terms or near-term revenue impact were disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
